Results 201 to 210 of about 2,221,794 (256)
Nutrimental Determinants of Chronological Aging and Competitiveness in the snf1Δ Warburg Model
Deletion of SNF1 in Saccharomyces cerevisiae alters chronological aging in a nutrient‐dependent manner, shortening lifespan under low‐nutrient conditions and extending it under high‐glucose and high‐amino‐acid conditions. Under nutrient‐rich conditions, the snf1∆ strain also showed an approximately 2‐log increase in competitiveness relative to the wild
Abigail Correa‐Olivares +7 more
wiley +1 more source
Interventional oncology in children: Where are we now?
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel +1 more
wiley +1 more source
Abstract Purpose To clinically validate the nursing diagnosis “Inadequate Nutritional Intake” based on elements identified within a specific situation theory framework in the context of children with cancer. Methods This is a diagnostic accuracy study following the Standards for Reporting Diagnostic Accuracy Studies (STARD) protocol.
Iane Ximenes Teixeira +7 more
wiley +1 more source
Building a precision therapeutics program at a tertiary care children's hospital
Pediatric Investigation, EarlyView.
Luke Hamilton +8 more
wiley +1 more source
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija +6 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Venetoclax in acute myeloid leukemia
Expert Opinion on Investigational Drugs, 2023Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia ...
Bruzzese, Antonella +8 more
openaire +4 more sources
Journal of the National Comprehensive Cancer Network, 2008
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell +19 more
openaire +5 more sources
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell +19 more
openaire +5 more sources
Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
Metabolomics in acute myeloid leukemia
Molecular Genetics and Metabolism, 2020Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki +3 more
openaire +2 more sources
Hematology, 2002
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles +5 more
openaire +2 more sources
AbstractIn this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and ...
Francis J, Giles +5 more
openaire +2 more sources

